Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254494 | 0.84 | NSD2 (0.39) | NSD2 | |
| Hydrochloric Acid SCHEMBL3503399 | 0.81 | ALK (0.35) | NSD2ALK | |
| SCHEMBL4301154 | 0.76 | APAF1 (0.39) | NSD2PDE10AHCRTR1HCRTR2 | |
| SCHEMBL2892863 | 0.74 | SMN1; SMN2 (0.40) | PDE10A | |
| SCHEMBL13282478 | 0.73 | ELANE (0.33) | — | |
| SCHEMBL3502900 | 0.73 | RXFP1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL13254490 | 0.73 | ELANE (0.34) | — | |
| SCHEMBL2897227 | 0.72 | HTR3E (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL16502027 | 0.71 | ALK (0.40) | NSD2ALKMAPK10 | |
| SCHEMBL2891999 | 0.71 | GRIN2D (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927569-B2 | Macrocyclic compounds as antiviral agents | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2178902-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-11-28 | — | — | EP | disclosed |
| US-20100183551-A1 | Macrocyclic Compounds As Antiviral Agents | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183551-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, RNASE1, RRP1B | NSD2 1079/4885FFAR2 4504/4885ALK 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.